Iambic Reports Q3 2026 Financial Results and AI Progress

Biotechnology

Earnings
IPO:
Oct 15, 2026
Industry:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Iambic Reports Third Quarter 2026 Financial Results and Business Updates
San Diego, California - Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company, has released its business and financial results for the third quarter ended September 30, 2026. The company continues to advance its AI-driven molecular superintelligence platform, marked by the launch of Enchant v3, a 41-billion-parameter transformer model designed to enhance drug discovery.
Key Highlights:
... Read on — Members only
About Iambic Therapeutics, Inc.
We are a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry. Our mission is to make better technology for better medicines. We do this by integrating leading proprietary, large-scale artificial intelligence (AI) with automated, scalable chemistry and biology experimentation. We call this approach molecular superintelligence.
















